- First phase investment of more than €70 million
- The facility is designed to operate 2000L scale
single-use bioreactors and fill/finish capabilities
- It is the first and only biopharmaceutical
manufacturing site established by a multinational active pharmaceutical
company in China
INGELHEIM, Germany & SHANGHAI--(BUSINESS
WIRE/ME NewsWire)-- Today,
Boehringer Ingelheim inaugurated its commercial production site for
biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site,
with the first-phase investment of more than €70 million, is the first and only
biopharmaceutical facility established by a leading multinational active
biopharmaceutical manufacturer in China utilizing mammalian cell culture
technology. With its global network of biopharmaceutical production sites in
Biberach ( Germany), Vienna (Austria), Fremont (USA) and now Shanghai, the
contract manufacturing business Boehringer Ingelheim BioXcellence™ is well
positioned to fulfil strongly increasing demands of the biopharmaceutical
industry for innovative products – both in China and worldwide.
“Our Shanghai facility plays an
important role in our globally leading biopharmaceutical contract manufacturing
business and embodies our continuous and long-term commitment to China,” said
Hubertus von Baumbach, Chairman of the Board of Managing Directors at
Boehringer Ingelheim. “With this investment, we expect to have a significant
impact on the development of China’s biopharmaceutical industry to ultimately
supply innovative medicines to patients following high quality standards.”
Boehringer Ingelheim has made this
strategic move with the long-term goal to become a leader for contract
development and manufacturing of monoclonal antibodies and recombinant proteins
in China. Since 2014, Boehringer Ingelheim China Biopharmaceuticals has been
operating its Good Manufacturing Practice (GMP) clinical material supply at
100L and 500L scales. After its inauguration, the facility will operate for
clinical and commercial supply on a 2000L single-use bioreactor scale. It is
designed to flexibly add additional 2000L single-use bioreactors and
fill/finish capabilities to meet increasing market demand.
“As a global leader in biopharmaceutical
contract manufacturing, Boehringer Ingelheim has an extraordinarily long
history in the field of biotechnology, having been in the industry for over 35
years,” said Dr Luo Jiali, General Manager of Boehringer Ingelheim
Biopharmaceuticals (China) Co Ltd. “We offer tailor-made contract development
and manufacturing services to the biopharmaceutical industry, providing the
entire production technology chain from DNA to the finished product under one
roof. With our strong know-how, global network, technology, and international
quality standards we can support innovative Chinese and international
companies to industrialize their research results.”
Boehringer Ingelheim
Innovative medicines for people and
animals have for more than 130 years been what the research-driven
pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is
one of the pharmaceutical industry’s top 20 companies and to this day remains
family-owned. Day by day, some 50,000 employees create value through innovation
for the three business areas human pharmaceuticals, animal health and
biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim
achieved net sales of around 15.9 billion euros. With more than three billion
euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes
naturally to Boehringer Ingelheim. That is why the company is involved in
social projects such as the “Making More Health” initiative. Boehringer
Ingelheim also actively promotes workforce diversity and benefits from its
employees’ different experiences and skills. Furthermore, the focus is on
environmental protection and sustainability in everything the company does.
More information about Boehringer
Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
Boehringer Ingelheim BioXcellence™
Boehringer Ingelheim is one of the world’s
largest manufacturers of biopharmaceuticals. With over 35 years of experience
in this field, the company is an industry pioneer and has produced more than 25
biopharmaceuticals for global markets. Represented by the brand Boehringer Ingelheim
BioXcellence™, it offers tailor-made contract development and manufacturing
services to the industry, providing the entire production technology chain from
DNA to fill and finish through its network in Biberach (Germany), Vienna
(Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim
BioXcellence™ secures supply throughout the entire product lifecycle —
transferring customer projects at any stage, delivering to almost any scale and
thereby making outsourcingeasy.For more information please visit www.bioxcellence.com